CRTX
NEUTRALCRISM Therapeutics Provides Shareholder Update
The healthcare company has released an update on its shareholder register, detailing the top investors in the business.
CRISM Therapeutics Corporation
10.72GBX
2.10%
Market Cap
5.55M
Volume
12.06k
11% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
0.36
Day Range
10.00p - 10.74p
52 Week Range
5.64p10.72p29.40p
10.72p
Upcoming Events
CRTX
NEUTRALCRISM Therapeutics Completes Retail Offer, Raises £59,610
The biotechnology company has completed a retail offer, raising £59,610 to fund its lead clinical program. The small raise size and minimal discount suggest reasonable demand, but the retail offer structure raises some concerns.
CRTX
NEUTRALCRISM Therapeutics Launches Retail Offer to Raise £100,000
The healthcare company is conducting a retail offer to raise funds for its clinical trial program.
CRTX
GOODCRISM Therapeutics Raises £1 Million in Oversubscribed Placing
The healthcare company has raised £1 million through an oversubscribed share placing to fund its Phase 2 clinical trial for its cancer treatment technology.
CRTX
NEUTRALCRISM Therapeutics Announces Change in Shareholding
The biotechnology company has reported a change in shareholding, with Spreadex LTD now holding a 2.94% stake.
CRTX
GOODCRISM Therapeutics Submits Orphan Drug Designation Application for Glioblastoma Treatment
The biotechnology company has submitted an application to the FDA for Orphan Drug Designation for its lead cancer treatment, marking an important regulatory milestone.
CRTX
NEUTRALCRISM Therapeutics Announces Positive Preclinical Data for Prostate Cancer Treatment
The drug delivery company has reported positive preclinical findings for its ChemoSeed platform in prostate cancer, as well as a new research collaboration.
CRTX
BADCRISM Therapeutics Reports Widening Losses as Phase 2 Trial Approaches
The clinical-stage drug delivery firm reports widening losses as it prepares for a Phase 2 trial. Despite progress with its ChemoSeed technology, financial challenges and funding needs cast a shadow over its near-term outlook.
CRTX
NEUTRALCRISM Therapeutics Provides Interim Results Update
The biotechnology company will announce its interim results and host an investor presentation to discuss its upcoming Phase 2 trial.
CRTX
NEUTRALCRISM Therapeutics Receives Approval for Phase 2 Glioblastoma Trial
The drug delivery company has received approval to begin a Phase 2 trial of its cancer treatment for glioblastoma, a significant step forward in its clinical development.